Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1101-1113

Bentham Science Publishers

Access to resources Recommend Favorite

L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 11, Iss. 4, 2011-12 ,pp. : 305-320

Bentham Science Publishers

Access to resources Recommend Favorite

New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

By Blandini Fabio   Armentero Marie-Therese  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 2, 2012-02 ,pp. : 153-168

Informa Healthcare

Access to resources Recommend Favorite

Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

By Lane Emma   Dunnett Stephen  

Psychopharmacology, Vol. 199, Iss. 3, 2008-08 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite